PDT Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.36M	Sell	563,440 -119,976	-18%	-$932K	0.32%	101
2025 Q4	$5.33M	Hold	683,416	–	–	0.35%	89
2025 Q3	$5.19M	Hold	683,416	–	–	0.33%	98
2025 Q2	$6.12M	Sell	683,416 -95,313	-12%	-$888K	0.35%	69
2025 Q1	$5.84M	Buy	778,729 +256,439	+49%	+$2.07M	0.41%	45
2024 Q4	$3.93M	Buy	522,290 +10	+0%	+$76	0.35%	78
2024 Q3	$3.97M	Buy	522,280 +155,510	+42%	+$1.18M	0.35%	60
2024 Q2	$2.27M	Sell	366,770 -13,753	-4%	-$75.9K	0.21%	173
2024 Q1	$1.93M	Buy	380,523 +69,325	+22%	+$390K	0.18%	198
2023 Q4	$1.86M	Buy	311,198 +40,489	+15%	+$235K	0.21%	159
2023 Q3	$1.92M	Buy	270,709 +71,630	+36%	+$515K	0.24%	138
2023 Q2	$1.4M	Buy	199,079 +88,626	+80%	+$711K	0.19%	183
2023 Q1	$921K	Buy	110,453 +49,573	+81%	+$477K	0.12%	280
2022 Q4	$699K	Sell	60,880 -3,269	-5%	-$40.8K	0.11%	324
2022 Q3	$808K	Buy	+64,149	New	+$826K	0.12%	285
2020 Q3	–	Sell	-86,518	Closed	-$412K	–	724
2020 Q2	$412K	Buy	+86,518	New	+$346K	0.03%	455
2017 Q3	–	Sell	-129,200	Closed	-$718K	–	519
2017 Q2	$718K	Hold	129,200	–	–	0.03%	370
2017 Q1	$1.08M	Sell	129,200 -1,594	-1%	-$11.1K	0.06%	312
2016 Q4	$828K	Sell	130,794 -31,106	-19%	-$162K	0.05%	350
2016 Q3	$714K	Buy	+161,900	New	+$647K	0.04%	342
2015 Q3	–	Sell	-74,960	Closed	-$1.12M	–	1268
2015 Q2	$1.12M	Buy	+74,960	New	+$852K	0.03%	706
2014 Q4	–	Sell	-70,474	Closed	-$689K	–	657
2014 Q3	$689K	Sell	70,474 -30,040	-30%	-$368K	0.02%	838
2014 Q2	$1.28M	Buy	100,514 +60,540	+151%	+$589K	0.03%	607
2014 Q1	$423K	Sell	39,974 -51,126	-56%	-$545K	0.01%	1021
2013 Q4	$692K	Buy	91,100 +57,043	+167%	+$361K	0.08%	311
2013 Q3	$248K	Buy	+34,057	New	+$173K	0.01%	1328